Arax Advisory Partners’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SL
Arax Advisory Partners's IKT Position: Q3 2026 in Review
Arax Advisory Partners increased its Inhibikase Therapeutics (IKT) stake by 664% in Q3 2026, buying an estimated $108K and bringing the position to 54,421 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #2739.
Arax Advisory Partners first reported a position in IKT in Q3 2025 and has held it in 4 quarters since. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.
- Arax Advisory Partners held 54,421 shares of Inhibikase Therapeutics worth $112K as of Q3 2026.
- Arax Advisory Partners bought 47,300 Inhibikase Therapeutics shares in Q3 2026, an estimated $108K.
- Inhibikase Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #2739 holding.
- Arax Advisory Partners first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 4 quarters since.
- 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.